AMG 794, a Claudin 6-targeted half-life extended (HLE) bispecific T cell engager (BITE®) molecule for non-small cell lung cancer and epithelial ovarian cancer.

被引：0

作者：

Pham, Elizabeth ^{[1
]}

Henn, Anja ^{[2
]}

Sable, Beate ^{[3
]}

Wahl, Joachim ^{[2
]}

Conner, Kip ^{[1
]}

Matthes, Katja ^{[2
]}

Gupta, Shivani ^{[1
]}

Yabut, Rodolfo ^{[1
]}

Aeffner, Famke ^{[1
]}

Wilson, Kristin Lewis ^{[1
]}

Anlahr, Jonas ^{[2
]}

Dahlhoff, Christoph ^{[2
]}

Kale, Vijay ^{[1
]}

Friedrich, Matthias ^{[2
]}

Raum, Tobias ^{[2
]}

Kufer, Peter ^{[2
]}

Coxon, Angela ^{[3
]}

Stienen, Sabine ^{[2
]}

Bailis, Julie M. ^{[1
]}

机构：

[1] Amgen Inc, San Francisco, CA USA

[2] Amgen Res Munich GmbH, Munich, Germany

[3] Amgen Inc, Thousand Oaks, CA 91320 USA

来源：

CANCER RESEARCH | 2022年 / 82卷 / 12期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

5202

引用

页数：2

共 50 条

[41] LunX-CAR T Cells as a Targeted Therapy for Non-Small Cell Lung Cancer
Hu, Ziming
Zheng, Xiaohu
Jiao, Defeng
Zhou, Yonggang
Sun, Rui
Wang, Baolong
Tian, Zhigang
Wei, Haiming
MOLECULAR THERAPY-ONCOLYTICS, 2020, 17 : 361 - 370
[42] Targeted COX-2 and EGFR TK inhibition in advanced non-small cell lung cancer.
Reckamp, K. L.
Czernin, J.
Weber, W. A.
Dubinett, S. M.
Figlin, R. A.
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 408S - 408S
[43] Low claudin-6 expression correlates with poor prognosis in patients with non-small cell lung cancer
Wang, Qiang
Zhang, Yan
Zhang, Tao
Han, Zhi-Gang
Shan, Li
ONCOTARGETS AND THERAPY, 2015, 8 : 1971 - 1977
[44] The role of extracorporeal life support in extended lung resections for non-small cell lung cancer: a narrative review
Lorenzi, William
Mercier, Olaf
JOURNAL OF THORACIC DISEASE, 2023, 15 (09) : 5232 - 5238
[45] Variation of use of targeted therapies and molecular diagnostic testing by practice type for non-small cell lung cancer and colorectal cancer.
Roberts, Thomas
Kehl, Kenneth L.
Brooks, Gabriel A.
Sholl, Lynette M.
Wright, Alexi A.
Bai, Barbara
Landrum, Mary Beth
Keating, Nancy Lynn
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[46] Pharmacokinetics of Tarlatamab, a Delta-Like Ligand-3 (DLL3) Targeted Half-Life Extended Bispecific T-Cell Engager (BiTE®) Immunotherapy in Adult Patients with Previously Treated Small-Cell Lung Cancer: Results from DeLLphi-300, a Phase I Multiple-Dose-Escalation Study
Minocha, Mukul
Thompson, Corbin G.
Murphy, Alexis
Zhou, Yanchen
Brandl, Christian
Parkes, Amanda
Chen, Xi
Yu, Brian
Martinez, Pablo
Houk, Brett E.
CLINICAL PHARMACOKINETICS, 2024, 63 (12) : 1757 - 1768
[47] Preliminary Results from a Phase 1 First-in-Human Study of AMG 673, a Novel Half-Life Extended (HLE) Anti-CD33/CD3 BiTE® (Bispecific T-Cell Engager) in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
Subklewe, Marion y
Stein, Anthony
Walter, Roland B.
Bhatia, Ravi
Wei, Andrew H.
Ritchie, David
Bucklein, Veit
Vachhani, Pankit
Dai, Tian
Hindoyan, Antreas
Agarwal, Suresh
Anderson, Abraham
Khaldoyanidi, Sophia
Ravandi, Farhad
BLOOD, 2019, 134
[48] Peripheral blood t cell responses to immunotherapy related adverse events in metastatic non-small cell lung cancer.
Amara, Suneetha
Muzaffar, Mahvish
Namireddy, Praveen
Yang, Li V.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[49] Exploration of long non-coding RNA involved in epithelial mesenchymal transition in non-small cell lung cancer.
Yoshimoto, Taichiro
Matsubara, Daisuke
Komura, Daisuke
Ishikawa, Syumpei
Niki, Toshiro
CANCER SCIENCE, 2018, 109 : 602 - 602
[50] Quality of life of survivors of non-small cell lung cancer. Overview of associated factors and requirements for aftercare
Hechtner, Marlene
Eichler, Martin
Buhl, Roland
Wehler, Beatrice
Sebastian, Martin
Blettner, Maria
Singer, Susanne
ONKOLOGE, 2018, 24 (12): : 1015 - 1022

← 1 2 3 4 5 →